Validity of Luminex and Enzyme-Linked Immunosorbent Assay Measuring Vascular Endothelial Growth Factor and Six Cytokines Quantitatively in Bone Marrow Aspiration Supernatant: Pilot Study

被引:2
作者
Cho, Chi-Hyun [1 ,3 ]
Park, Min-Chul [2 ]
机构
[1] Korea Univ Ansan Hosp, Coll Med, Dept Lab Med, Ansan, Gyeonggi, South Korea
[2] Korea Inst Sci & Technol, Ctr Optoelect Mat & Devices, Seoul, South Korea
[3] Korea Univ Ansan Hosp, Coll Med, Dept Lab Med, 123 Jeokgeum Ro,Danwon Gu, Ansan 15355, GuamGyeonggi, South Korea
基金
新加坡国家研究基金会;
关键词
bone marrow; VEGF; cytokine; hematological malignancy; Luminex; ELISA; VEGF; CANCER;
D O I
10.1478/annals.0235
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objective. Vascular endothelial growth factor (VEGF) and other cytokines have been reported to be implicated in the molecular pathogenesis of hematologic malignancy. However, a quantitative measure-ment of VEGF and related cytokines is necessary to reflect the real situation in the bone marrow (BM). Currently, no such quantitative assays exist for use in the BM supernatant as their concentrations have not been previously validated in the BM. Here we performed linearity and recovery tests to quantitatively mea-sure the concentrations of VEGF and six related cytokines in the BM. Method. A total of 24 BM superna-tant samples were collected from patients who underwent a BM examination for hematological malignan-cies. The levels of VEGF and six cytokines -granulocyte colony-stimulating factor (G-CSF), interferon -(3 (INF -(3), interleukin (IL)-1(3, IL-6, IL-17A, and tumor necrosis factor-alpha (TNF-alpha) -were measured using Luminex assay and enzyme-linked immunosorbent assay. Percentage recovery and linearity were calculated, with the acceptable range being 80-120%. The undiluted and diluted (1:2, 1:4, and 1:8) concentrations of VEGF and the six cytokines in 24 spiked and unspiked BM supernatant samples and controls were also measured. Results. For VEGF, both assays passed the percentage recovery and linearity tests; wherein the undiluted and all diluted concentrations of VEGF in all six unspiked BM samples showed linearity parallel to those of VEGF in spiked BM samples and controls. For the other six cytokines, both assays did not pass the percentage recovery and linearity tests, with the undiluted and diluted concentrations in all seventeen unspiked BM samples (except G-CSF in one sample) showing a lack of parallelism to those in spiked BM samples and controls. Conclusions. Quantitative VEGF measurement in real BM specimens was validated using both Luminex assay and ELISA. All six cytokines, except for VEGF, whether undiluted or diluted, could not be accurately measured in the BM supernatants, indicating the presence of inhibitors to the ana-lytes. Quantitative measurement of VEGF-related cytokines in the BM will have to be validated in further studies with more samples.
引用
收藏
页码:663 / 676
页数:14
相关论文
共 10 条
[1]   VEGF in Signaling and Disease: Beyond Discovery and Development [J].
Apte, Rajendra S. ;
Chen, Daniel S. ;
Ferrara, Napoleone .
CELL, 2019, 176 (06) :1248-1264
[2]   Comparative study of bone marrow and blood plasma levels of IL-2 in aplastic anaemia and their relationship with disease severity [J].
De, Rajib ;
Dutta, Atreyee ;
Dolai, Tuphan Kanti ;
Ghosh, Kakoli ;
Halder, Ajanta .
HEMATOLOGY, 2019, 24 (01) :84-88
[3]   Bone Marrow Stromal Cell-Derived Vascular Endothelial Growth Factor (VEGF) Rather Than Chronic Lymphocytic Leukemia (CLL) Cell-Derived VEGF Is Essential for the Apoptotic Resistance of Cultured CLL Cells [J].
Gehrke, Iris ;
Gandhirajan, Rajesh Kumar ;
Poll-Wolbeck, Simon Jonas ;
Hallek, Michael ;
Kreuzer, Karl-Anton .
MOLECULAR MEDICINE, 2011, 17 (7-8) :619-627
[4]   Molecular origins of cancer: Tumor angiogenesis [J].
Kerbel, Robert S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (19) :2039-2049
[5]   Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer [J].
Kut, C. ;
Mac Gabhann, F. ;
Popel, A. S. .
BRITISH JOURNAL OF CANCER, 2007, 97 (07) :978-985
[6]   Targeting the vascular endothelial growth factor in hematologic malignancies [J].
Paesler, Julian ;
Gehrke, Iris ;
Poll-Wolbeck, Simon Jonas ;
Kreuzer, Karl-Anton .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 89 (05) :373-384
[7]  
Semesiuk N., 2013, Experimental Oncology, V35, P295
[8]   Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia [J].
Verstovsek, S ;
Kantarjian, H ;
Manshouri, T ;
Cortes, J ;
Giles, FJ ;
Rogers, A ;
Albitar, M .
BLOOD, 2002, 99 (06) :2265-2267
[9]   Bone Marrow Cells in Acute Lymphoblastic Leukemia Create a Proinflammatory Microenvironment Influencing Normal Hematopoietic Differentiation Fates [J].
Vilchis-Ordonez, Armando ;
Contreras-Quiroz, Adriana ;
Vadillo, Eduardo ;
Dorantes-Acosta, Elisa ;
Reyes-Lopez, Alfonso ;
Martin Quintela-Nunez del Prado, Henry ;
Venegas-Vazquez, Jorge ;
Mayani, Hector ;
Ortiz-Navarrete, Vianney ;
Lopez-Martinez, Briceida ;
Pelayo, Rosana .
BIOMED RESEARCH INTERNATIONAL, 2015, 2015
[10]   Characterization of Growth Factors, Cytokines, and Chemokines in Bone Marrow Concentrate and Platelet-Rich Plasma: A Prospective Analysis [J].
Ziegler, Connor G. ;
Van Sloun, Rachel ;
Gonzalez, Sabrina ;
Whitney, Kaitlyn E. ;
DePhillipo, Nicholas N. ;
Kennedy, Mitchell, I ;
Dornan, Grant J. ;
Evans, Thos A. ;
Huard, Johnny ;
LaPrade, Robert F. .
AMERICAN JOURNAL OF SPORTS MEDICINE, 2019, 47 (09) :2174-2187